JAK Janus Kinase

(Unterschied zwischen Versionen)

Wechseln zu: Navigation, Suche

Version vom 11. April 2021, 19:37 Uhr

32584421 2020. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer.

32278797 ä. The use of Janus kinase inhibitors in the time of SARS-CoV-2
32339701 ä. Potential role of Janus kinase inhibitors in COVID-19
32344070 ä. Calm before the storm: understanding the role of JAK inhibitors in COVID-19

32535597 2020. Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19.

32385052 2020. ...The potential role of JAK inhibitors in the management of COVID-19.
32392562 2020. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
32584762 2020. [Rationales for using JAK 1/2 inhibitors in severely afflicted patients with COVID-19 pneumonia].
32537890 2020. Observation and consideration on using of JAKi in clinical trials in times of COVID-19.
32580895 2020. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.

Tofacitinib

32342098 ä. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib

Fedratinib

32205092 ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

Jaktinib
32536632 2020. Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19.

Methotrexate mtx
32454489 2020. JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.

@@ Zeile 1: / Zeile 1: @@
 {{up|PHA Biologicals}}
 {{qt|Baricitinib}}
+{{qt|Ruxolitinib}}
 {{ttp|p=32584421|t=2020. Combined IL-6 and JAK-STAT inhibition therapy in COVID-19 related sHLH, potential game changer.|pdf=|usr=011}}
@@ Zeile 23: / Zeile 24: @@
 {{ttp|p=32205092|t=ä. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib |pdf=|usr=}}
-'''Ruxolitinib'''
-{{tp|p=32450201|t=2020. Side effects of ruxolitinib in patients with SARS-CoV-2 infection: Two case reports.|pdf=|usr=008}}
-{{tp|p=32470486|t=2020. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial.|pdf=|usr=008}}
-{{tp|p=32405693|t=2020. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?|pdf=|usr=008}}
-{{tp|p=32518419|t=2020. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.|pdf=|usr=009}}
-{{tp|p=32528040|t=2020. Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.|pdf=|usr=009}}
-{{tp|p=32585295|t=2020. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.|pdf=|usr=010}}
-{{tp|p=32555296|t=2020. Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).|pdf=|usr=010}}
-{{tp|p=32593183|t=2020. Ruxolitinib for tocilizumab-refractory severe COVID-19 infection.|pdf=|usr=011}}
-{{tp|p=32581810|t=2020. Combination of Ruxolitinib and Eculizumab for Treatment of Severe SARS-CoV-2-Related Acute Respiratory Distress Syndrome: A Controlled Study.|pdf=|usr=011}}
 '''Jaktinib'''

JAK Janus Kinase

Version vom 11. April 2021, 19:37 Uhr

Meine Werkzeuge

Namensräume

Varianten

Ansichten

Aktionen

Suche

Navigation

Werkzeuge